期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌应用的瓶颈——获得性耐药 被引量：4

The Bottleneck of EGFR-TKI Application in Non-Small Cell Lung Cancer—Acquired Resistance
下载PDF
导出
摘要 以表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI）分子靶向治疗研究为肇始，转化性研究使基础实验和临床实践间的鸿沟迅速填平，改变着人们认识治疗肺癌的视角。无可否认，EGFR-TKI上市后极大地延伸了肿瘤学家治疗肺癌的手段，但不管从临床经验、临床研究数据、分子生物学层面还是文献计量学的角度，
作者 钟文昭 吴一龙
机构地区 广东省人民医院肿瘤中心
出处 《循证医学》 CSCD 2008年第4期193-197,共5页 The Journal of Evidence-Based Medicine
关键词 肺肿瘤 表皮生长因子受体酪氨酸激酶抑制剂 获得性耐药 T790M c-Met扩增 KRAS 不可逆性酪氨酸激 酶抑制剂 MTOR抑制剂 MET抑制剂 IGFIR lung neoplasms epidermal growth factorreceptor-tyrosine kinase inhibitor acquired resistance T790M c-Met amplification KRAS irreversible tyrosine kinaseinhibitors roTOR inhibitors MET inhibito IGFIR
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to Gefitinib[J].N Engl J Med, 2005, 352(8):786-792.
  • 2Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to Gefitinib or Erlotinib is associated with a second mutation in the EGFR kinase domain [J]. PLoS Med, 2005, 2(3):e73.
  • 3Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer[J]. Cancer Res, 2006, 66(16) : 7854-7858.
  • 4Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nat Genet, 2005, 37(12) : 1315-1316
  • 5Jackman DM, Hohnes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose Gefitinib[J]. J Clin Oncol, 2006, 24(27) :4517-4520.
  • 6Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to Gefitinib[J].Proc Natl Acad Sci USA, 2005, 102(21 ):7665-7670.
  • 7Li D, Shimamura T, Ji H, et al. Bronchial and peripheral routine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy [J]. C Cell, 2007, 12(1) :81-93.
  • 8Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827):1039-1043.
  • 9Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer[J]. J Clin Invest, 2006, 116(10) :2695-2706.
  • 10Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in Gefitinib-sensitive non-small cell lung cancer cell lines[J]. Proc Natl Acad Sci USA, 2005, 102(10) :3788-3793.

同被引文献41

  • 1BaoMingQIN,XiaoCHEN,JingDeZHU,DuanQingPEI.Identification of EGFR kinase domain mutations among lung cancer patients in China:implication for targeted cancer therapy[J].Cell Research,2005,15(3):212-217. 被引量：66
  • 2Tsao MS, Liu G, Shepherd FA. Serum proteornic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap? J Nail Cancer Inst, 2007, 99(11): 826-827.
  • 3Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics, 2007, 4(1): 51-65.
  • 4Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption- ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res, 2006, 66(11): 5540-5541.
  • 5Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spec- trometry. Clin Chem, 2007, 53(5): 852-858.
  • 6Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372(9652): 1809-1818.
  • 7Kima HS, Parka K, Juna HJ, et al. Comparison ofsurviva/in advanced nonsmall cell lung cancer patients in the pre- and post-gefifinib eras. Oncology, 2009, 76(4): 239-246.
  • 8Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N EnglJ Med, 2005, 352(8): 786-792.
  • 9Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non- small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort crossinstitutional study. J Nail Cancer Inst, 2007, 99(11): 838-846.
  • 10ViUanueva J, Philip J, DeNoyer L, et al. Data analysis of assorted serum peptidome profiles. Nat Prot, 2007, 2(3): 588-602.

引证文献4

二级引证文献16

循证医学
2008年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部